Abstract:Abstract Background Based on its low toxicity, arginine starvation therapy has the potential to cure malignant tumors that cannot be treated surgically. The Arginine deiminase (ADI) gene has been identified to be an ideal cancer-suppressor gene. ADI expressed in the cytosol displays higher oncolytic efficiency than ADI-PEG20 (Pegylated Arginine Deiminase by PEG 20,000). However, it is still unknown whether cytosolic ADI has the same mechanism of action as ADI-PEG20 or other underlying cellular mechanisms. Methods The interactions of ADI with other protein factors were screened by yeast hybrids, and verified by co-immunoprecipitation and immunofluorescent staining. The effect of ADI inhibiting the ferritin light-chain domain (FTL) in mitochondrial damage was evaluated by site-directed mutation and flow cytometry. Control of the mitochondrial apoptosis pathway was analyzed by Western Blotting and real-time PCR experiments. The effect of p53 expression on cancer cells death was assessed by siTP53 transfection. Chromatin autophagy was explored by immunofluorescent staining and Western Blotting. Results ADI expressed in the cytosol inhibited the activity of cytosolic ferritin by interacting with FTL. The inactive mutant of ADI still induced apoptosis in certain cell lines of ASS- through mitochondrial damage. Arginine starvation also generated an increase in the expression of p53 and p53AIP1, which aggravated the cellular mitochondrial damage. Chromatin autophagy appeared at a later stage of arginine starvation. DNA damage occurred along with the entire arginine starvation process. Histone 3 (H3) was found in autophagosomes, which implies that cancer cells attempted to utilize the arginine present in histones to survive during arginine starvation. Conclusions Mitochondrial damage is the major mechanism of cell death induced by cytosolic ADI. The process of chromatophagy does not only stimulate cancer cells to utilize histone arginine but also speeds up cancer cell death at a later stage of arginine starvation.

Targeting arginine metabolism pathway to treat arginine-dependent cancers.

Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer

Targeted Arginine Metabolism Therapy: A Dilemma in Glioma Treatment

Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment

Targeting the L-arginine-nitric Oxide Pathway for Cancer Treatment.

Targeting amino acid metabolism for cancer therapy

Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase

Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression

Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies

Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy

Study on the new target of the individual treatment of breast cancer by argininosuccinate synthetase 1

Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies

Targeting the glutamine-arginine-proline metabolism axis in cancer

Arginine deiminase produced by lactic acid bacteria as a potent anti-cancer drug

Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination

Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy

Targeting glutamine metabolism as a therapeutic strategy for cancer

Amino acid metabolism as a therapeutic target in cancer: a review

Arginine deprivation: a potential therapeutic for cancer cell metastasis? A review

Influence of arginine on protein metabolism of tumor and host in cancer-bearing status